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Abstract
The genogroups of meningococcal and other bacteria are in competition in the
ecosystem they form with the human hosts. Changes in vaccination strategies,
prophylactic measures or usual habits, may also change the distribution of the
genogroups in the ecosystem but, usually, this competition is ignored in most epi-
demiological models, despite it can be highly influential in the evolution of infection
diseases and outbreaks.
Our goal is to propose a susceptible-carrier-susceptilbe (SCS) epidemiological
model to determine the percentage of carriers in the population, and introduce
a fractional Lokta-Volterra competition model to describe the evolution of the
meningococcal genogroups in Spain among the carriers.
Using data from the distribution of the genogroups in Spain in 2011 and 2012, we
find the model parameters and their uncertainties according to a probabilistic fitting
approach. On this basis, we predict the evolution of the carriers of the different
genogroups over the next few years and, in particular, the percentage of carriers
of meningococcus W-135 with a 95% confidence interval. Then, we estimate the
probability of having a possible outbreak of meningococcus W-135 in Spain over
the next few years. According to our model and, under the present conditions, the
risk of a serious outbreak of W-135 in Spain in the next 3 years is below 0.3%.
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1 Introduction
Meningococcal disease is caused by the bacterium Neisseria meningitidis, also
called meningococcus. About 10% of people have this type of bacteria in the
back of their nose and throat with no signs or symptoms of the disease, being
called carriers. But sometimes Neisseria meningitidis bacteria can invade the
body causing certain illnesses, which are known as meningococcal diseases [1].
The disease, Meningitis, is an infection of the brain and spinal cord and can
even infect the blood. Nowadays, the main cause of Meningitis is the bacterium
Neisseria meningitidis. This bacterium is transmitted exclusively among hu-
mans, mainly during adolescence. An individual may get infected by contact
with a carrier individual, that is, healthy carriers transmit the bacteria. It is
treated with specific antibiotics, however, even properly treated, there is up
to 10% of mortality and 10% of survivors have sequelae [2,3].
On the one hand, there are 12 types or genogroups of Meningococcus based
on the capsular polysaccharides: A, B, C, H, I, K, L, X, Y, Z, E and W, but
90% of all infections are caused by types A, B, C, Y and W, being A, B and C
the most common (W-cases are only the 4% in US). On the other hand, the
type A has been the most prevalent in Africa and Asia, but is rare in North
America and Europe.
In Spain the major concern in the last decades has been the infection by
the serogroups C and B. In particular, Neisseria meningitidis serogroup C
(MenC) was the leading cause of meningococcal disease in Spain in the late
1990s. Men C mainly impacted on the infants and toddlers populations but
also on adolescents and young adults, which also acted as carriers of the disease
and spreaded the disease among other age groups. After controlling MenC by
vaccination campaigns and recent revisions and booster doses, we can fairly say
that MenC disease prevalence has greatly decreased in Spain [4]. On the other
hand, Public Health responsibles and Meningitis experts are now concerned
about the fact that the ecological niche left by the waning serogroup could be
occupied by another serogroup such as B or the even more lethal, W-135.
The serogroup W-135 origin has been traced back to Africa where it has
competed with serogroup A and other in the so-called sub-Saharan Africa
Meningitis belt. Since the early 2000s, the W-135 it is known to be associated
with outbreaks of the Meningitis disease after the annual Hajj pilgrimage to
Mecca [5]. The disease appeared also in Europe in 2000 and as early as April
2000 four children with W-135 Meningitis were treated in London. The situa-
tion became severe in Chile in 2012 when 133 cases of Invasive Meningococcal
Disease were reported and the 58% of the cases the serogroup W-135 were
identified. As a consequence, the fatality ratio peaked in Chile up to a 27%,
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being the largest in the last twenty years [6]. Isolated clinical cases have also
been reported in Spain since 2005, but no widespread epidemic by W-135 has
occurred.
We must take into account that Neisseria meningitidis bacteria are spread
through the exchange of respiratory and throat secretions like spit (e.g., living
in close quarters, kissing, sharing drinks, etc). Fortunately, these bacteria are
not as contagious as what causes the common cold or the flu. Besides, the bac-
teria are not spread by casual contact or by simply breathing the air where a
person with meningococcal disease has been. Sometimes Neisseria meningitidis
bacteria spreads to people who have had close or lengthy contact with a pa-
tient with meningococcal disease. People in the same household, roommates,
or anyone with direct contact with a patient’s oral secretions, meaning saliva
or spit, such as a boyfriend or girlfriend, would be considered at increased risk
of getting the infection [1].
Meningococcus is a part of the common flora in the nasopharynx of up to
5 − 15% of adults and the genogroups are in competition by this ecosystem
with humans. Thus, changes in health habits or prophylactic measures may
change the distribution of the genogroups in this ecosystem. The study of the
replacement of a genogroup by another as the most prevalent in the population
is a fundamental problem in epidemiology. This is even more evident in the
modern era of antibiotic resistant strains and vaccines selectively addressing
a given genogroup and allowing other to proliferate.
For these reasons, in this paper we will study a Lotka-Volterra competition
model coupled to a susceptible-carrier-susceptible (SCS) model for the trans-
mission of the meningococcal bacteria. Standard Lotka-Volterra model simu-
lates a predator-prey ecological system in which, the predator and prey popu-
lations interact and regulate each other. A different version of the model with
a logistic term for the evolution of the free population of each genogroup is
used for the interaction of different colonies, strains or genogroups compet-
ing for the same resources (or hosts, in the case of bacteria). Instead of the
original model based upon ordinary differential equations, we propose also
a generalization involving fractional derivatives. Fractional calculus is a tool
to describe some physical systems exhibiting hysteresis and viscoelastic prop-
erties but also other behaviour such as subdiffusion [7–9]. The order of the
fractional derivative is a parameter that could help us to estimate the ef-
fect of genetical changes in the strains and recombination which enhance the
adaptation to the host of the dominant genogroups.
From the epidemiological and clinical point of view, there have been some
recent interest in the W-135 specially after the outbreak in Chile [6], the sub-
sequent outbreaks associated with the Hajj’s pilgrims [5] and the vaccination
against W-135 carried out in UK as a prevention after the initial cases of dis-
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ease in which this strain was isolated [12]. Some models for the propagation
of meningococcal C and B diseases [10,11], and also for the relation among
prevalence of the infection and invasive disease [13] have also been studied re-
cently. Pérez-Breva et al. [14] have also analyzed an agent-based model for the
duration of immunity after vaccination of selected population age groups and
the consequences of improved vaccination strategies against meningococcal C
disease. Anyway, in the western countries, most of the cases are produced
by groups B and C. Genogroups Y and W are less frequent although there
are differences in their incidence in some countries. The genogroup W-135 is
associated to cases and outbreaks after traveling to Mecca [5].
The increasing number of cases in countries such as Chile and UK and the
high risk of mortality associated with this strain implies that the statistical
modelling of this pandemic is a hot topic in epidemiology. For these reasons we
will estimate the probability for an outbreak of meningococcal W-135 disease
[15] in Spain using a probabilistic fitting technique for the genogroup com-
petition SCS model discussed above. Our approach allows us to predict the
maximum increase of the number of carriers expected from the seroepidemio-
logical studies of 2011 and 2012 at the Reference Laboratory for Meningococci
of the Carlos III Institute of Health in Spain [4]. A different, but still unsolved
question, is the relationship among the number of carriers and the clinical
cases of invasive meningococcal disease. According to the experts this con-
nection is still uncertain but it is considered that even a 4% or 5% of the
total population being carriers of the W-135 serogroup could be alarming or,
at least, highly worrying. The probabilistic fitting technique would allow us
to show that, from the 2011 and 2012 seroepidemiological results the max-
imum number of carriers of W-135 in Spain would remain below 3% in the
next three years (excluding increasing immigration of infected individuals).
Consequently, an outbreak of meningococcal W disease is unlikely in the near
future.
The paper is organized as follows: In Section 2 we describe the Lotka-Volterra
competition model for the genogroups coupled to the SCS model for the human
hosts as well as the data provided by the Spanish Reference Laboratory for
Meningococci at the Carlos III Institute of Health. The probabilistic fitting
technique for obtaining the statistical distribution of the model parameters in
order to perform probabilistic predictions for the future is described in Section
3. The results and the evolution of the estimated number of carriers in the next
decade is shown in Section 4. The paper ends with some conclusions drawn in
Section 5.
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2 Lotka-Volterra competition model and SCS epidemilogical trans-
mission
In this section we will introduce the competition model for the meningococcal
genogroups as well as the susceptible-carrier-susceptible (SCS) model. These
equations describe the complex ecosystem composed by all the meningococci
genogroups and the human hosts. Firstly, we will give a summary of the data
obtained in the seroepidemiological study for all meningococcal genogroups
and, in particular, the W-135 strain.
2.1 Data
In this study, we use data provided by the Reference Laboratory for Meningo-
cocci of the Spanish Institute of Health Carlos III, collected in Tables 1 and 2,
for December, 2011 and December, 2012. These are currently the only available
data.
t1 = 2011 t2 = 2012
Sample size 3000 500
Susceptible population 2626 (87.53%) 409 (81.8%)
Carrier population 374 (12.47%) 91 (18.2%)
Table 1
Sample size, number and percentage of susceptible carriers of any meningococcus
in Spain in Dec 2011 and Dec 2012.
Dates Genotype W Other genotypes
t1 = 2011 4.3% 95.7%
t2 = 2012 5.5% 94.5%
Table 2
Percentage of carriers of the genotype Men W-135 in Spain in Dec 2011 and Dec
2012 among the carriers.
2.2 Susceptible-Carrier-Susceptible (SCS) model
Firstly, we state an epidemiological model in order to describe the trans-
mission dynamics of all the meningococci. This is a classical SIS type-model
where the ”infected” people is called ”carrier” in this case. Carriers are people
who carry meningococci bacteria and can transmit it to other people. Only
when meningococci invades the host, they get infected. As we indicated, the
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meningococci spreads through the exchange of respiratory and throat secre-
tions. The carriers clear the bacteria after some months becoming susceptible
again. The above transmission dynamics of meningococci can be modeled by
the following system of non-linear difference equations{
St+1 = St − βStCt + γCt,
Ct+1 = Ct + βStCt − γCt,
(1)
where St and Ct are the percentage of susceptible and carriers in the month t,
respectively, β is the transmission rate of meningococci and 1/γ is the average
time in moths a carrier individual clears the bacteria. A diagram of the model




Fig. 1. Diagram of Susceptible-Carrier-Susceptible (SCS) model in Eq. (1).
Taking into account that St and Ct are percentages and St + Ct = 1 we can
write the above system (1) with only the following equation
Ct+1 = (1 + β − γ)Ct − βC2t , (2)
which is a non-linear difference equation for the percentage of carriers, Ct, at
month t.
2.3 Lotka-Volterra’s competition model
The above model will give us the percentage of carriers in every time instant (in
months). But meningococci are in competition in their ecosystem. Therefore,
in order to understand the competition dynamics of the meningococcus W-
135 with respect to the others, we introduce the following Lotka-Volterra’s
continuous competition model of two speciesX
′
1(t) = r1X1(t)(K1 −X1(t))− α1,2X1(t)X2(t),
X ′2(t) = r2X2(t)(K2 −X2(t))− α2,1X2(t)X1(t),
(3)
where i = 1 corresponds to W-135 genogroup and i = 2 corresponds to non-
W-135 genogroup, and, for i, j = 1, 2, we have:
• Xi(t) is the total amount of the genotype i meningoccocus bacteria at the
time instant t,
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• ri > 0 is the growth rate of the genotype i meningoccocus bacteria,
• Ki > 0 is the carrying capacity of the genotype i meningoccocus bacteria,
• αi,j > 0 is the effect of the genotype j bacteria on the growth of the genotype
i bacteria.
Notice that in our model we assign a label to the genogroup W-135 in which
we are mostly interested, i = 1, but the collective composed by the other
genogroups is treated as a single group with i = 2.
Taking into account that data collected in Table 2 are in percentages and,
in order to combine the results of this model with those of the SCS model,





, i = 1, 2, (4)
which represents the percentage of ecosystem occupied by the i-th-genogroup.
It is easy to check that 0 ≤ xi(t) ≤ 1 and x1(t) + x2(t) = 1.
Introducing the change of variable in Eq. (4) into Eq. (3), this latter system
can be written asx
′
1(t) = r1x1(t)K1(1− x1(t))− α1,2K2x1(t)x2(t),
x′2(t) = r2x2(t)K2(1− x2(t))− α2,1K1x1(t)x2(t).
(5)
Finally, if we define Hi = riKi > 0, i = 1, 2, M1 = α1,2K2 > 0 and M2 =
α2,1K1 > 0, we have
{
x′1(t) = H1x1(t)(1− x1(t))−M1x1(t)x2(t),
x′2(t) = H2x2(t)(1− x2(t))−M2x1(t)x2(t),
(6)
where Hi and Mi, i = 1, 2, are the new parameters of the system. As in the
SCS model, taking into account that x1(t) + x2(t) = 1, we only consider the
first equation of (6), related with the dynamics of the meningococcus W-135,
x′1(t) = H1x1(t)(1− x1(t))−M1x1(t)(1− x1(t)),
that can be simplified as
x′1(t) = N1x1(t)(1− x1(t)), (7)
where N1 = H1 − M1. So, the competition dynamics is basically governed
by the Ricatti equation (7) in which the parameter N1 is given by the dif-
ference among the reproductive factor for the W-135 genogroup, H1, and the
competition parameter with the other genogroups, M1.
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2.3.1 The fractional Lotka-Volterra model
As we have mentioned in the introduction, the competition dynamics may
reinforce certain genogroups by DNA recombination or mutations and this
would depend on the other genogroups coexisting with them as well as the
time this coexistence lasts and their populations. In this spirit, we will ex-
tend the original Lotka-Volterra model to a generalized one in which ordinary
derivatives are replaced by fractional derivatives. It is well-known that frac-
tional differential equations may account for these memory effects as they are
usually applied to visco-elastic materials and subdiffusive processes [7,8].
So, we replace the first derivative of model (7) by a fractional Caputo derivative
of order α (0 < α < 1) [19]. This way, the model will be given by the following
expression:
CDαx1(t) = N1x1(t)(1− x1(t)), (8)
where CDα0 f denotes the fractional Caputo derivative of order α of the function
















Discretizing Eq. (8), we obtain the following expression,
(∆α∗x1) (t) = N1x1(t+ α− 1)(1− x1(t+ α− 1)) , (10)
where t ∈ N1−α := {1− α, 2− α, . . .}, and ∆∗α is the Caputo-like delta differ-
ence operator which, according to Atici and Eloe [19], represents the Caputo










where (∆x1) (t) is the discretization of the first derivative of x1(s) in discrete
time, i.e.,
(∆x1)(s) = x1(s)− x1(s− 1) . (12)
Moreover, by [18, Lemma 2.4], the difference system (10) can be rewritten as






Γ(t− s− α + 1)






Γ(t− k + α)
Γ(t− k + 1)
N1x1(k − 1)(1− x1(k − 1)),
(13)
where t is a positive integer. Denoting x1(t) = xt, the fractional Lotka-Volterra
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model in discrete time is formulated as





Γ(t− k + α)
Γ(t− k + 1)
N1xk−1(1− xk−1), (14)
where N1 and α are the model parameters to be determined and t is the
time in months. Notice that our competition-epidemiological model involves
now four parameters: the infection rate, β; the recovery rate, γ; the balance
among the W-135 genogroup reproduction and its competition parameter, N1;
and also the fractional index, α, for the Caputo derivative in Eq. (14). In the
next section we will show how to obtain probabilistic estimations of these four
parameters from the data collected in Tables 1 and 2. From these fitting we
will be able to predict reliable bounds on the evolution of W-135 prevalence
with 95% confidence and, consequently, to quantify the risk of outbreaks in
the near future.
3 Probabilistic Fitting
This technique, introduced in [15], consists of using information from surveys
to assign probability distributions to the data. Then, we sample data values
from these probability distributions and fit the model to the sampled data.
Thus, we find model parameters that fit not only the data but also the un-
certainty contained into the intrinsic survey error. Hence, these fitted model
parameters will allow the model to capture the data uncertainty (with 95%
confidence intervals).
We are going to apply probabilistic fitting to models (2) and (14).
3.1 Data 95% confidence intervals (95% CI)
Data in Table 1 correspond to the mean percentage of carriers in Dec 2011
and Dec 2012. Also, the sample sizes are 3000 and 500, respectively.
Assuming that the surveys are independent, for each one of the two available
surveys, let us denote by Xj = (Xj1 , X
j
2), 0 ≤ X
j
i ≤ nj, i, j = 1, 2, a random
vector whose entries are Xj1 = # Carriers, X
j
2 = # Susceptible, and n1 = 3000
and n2 = 500 being the sample sizes of the surveys corresponding to December
2011 (j = 1) and December 2012 (j=2), respectively.
For the sake of clarity, let us fix j = 1 and let us consider the random vec-
tor X1, but the same findings to be presented in the following, apply to the
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random vector X2 (j = 2). Initially, it is natural to assume that the ran-
dom variable X11 has a binomial distribution of parameters n1 = 3000 and p1,
X11 ∼ Bi(3000; p1). As a consequence, X12 = n − X11 ∼ Bi(3000, 1 − p1), see
Appendix A. However, as the available information from the data surveys is
limited to December 2011 (j = 1) and December 2012 (j = 2) only, we are
going to consider that the parameter p1 is a random variable rather than a
deterministic value. Furthermore, since p1 ∈ (0, 1) we will assume that p1 has
a beta distribution of parameters β11 and β
1
2 , p1 ∼ Be(β11 ; β12). At this time, it
is worth pointing out that beta distribution is a two parametric probabilistic
distribution whose domain is just the interval (0, 1), then allowing for enough
flexibility to describe, from a probabilistic standpoint, the parameter p1. This
approach leads us to assume that X11 has a beta-binomial distribution
X11 ∼ Bi(3000; p1), p1 ∼ Be(β11 ; β12),
whose probability mass function is given by









, k = 0, 1, . . . , 3000, (15)





As a consequence of the results collected in Appendix A for the second com-
ponent of the random vector X1 one gets
X12 = 3000−X11 ∼ Bi(3000, 1− p1), 1− p1 ∼ Be(β12 ; β11),
or equivalently, with p1 ∼ Be(β11 ; β12). Hence, the probability mass function of
X12 is given by









, k = 0, 1, . . . , 3000, (16)







been used to express the denominator of (16).
An analogous development follows for the random vector X2 = (X21 , X
2
2 ),
X21 ∼ Bi(500; p2), X22 ∼ Bi(500; 1− p2), p2 ∼ Be(β21 ; β22),









, k = 0, 1, . . . , 500, (17)









, k = 0, 1, . . . , 500. (18)
In order to estimate the parameters {β11 , β12} of the random variable p1 ∼
Be(β11 ; β
1




2 ), firstly we observe, from Table 1 that in
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December of 2011 (j = 1), the number of carriers was 374 out of 3000 individ-
uals. Hence a reasonable punctual estimation of p1 is
374
3000



















and then we apply the maximum likehood estimation (MLE)
technique. This turns out
β̂11 = 6.122 · 104 β̂12 = 4.2984 · 105. (19)













Following the analogous strategy, we have constructed the estimates (β̂21 , β̂
2
2)
for the parameters (β21 , β
2
2) of the random variable p2 ∼ Be(β21 ; β22) and hence
of (X21 and X
2












. This figure comes from Table 1, since in December 2012 (j=2),
the number of sample data being carrier was 91 out of 500 individuals.In this
case, the application of MLE method turns out the estimates
β̂21 = 3.387 · 103 β̂22 = 1.5221 · 104. (20)
This estimates also satisfies E[p2] = β̂21/(β̂21 + β̂22) = 91500 .
Now we compute the percentiles 2.5 and 97.5 in order to determine 95%
CI (confidence intervals) of each random vector X1 = (X11 , X
1




2 ). These intervals are computed using the probability mass functions
given by (15)–(18) and the estimates (19)–(20). The 95% CI are collected in
Table 3.
Dates Carriers (Xj1) Susceptible (X
j
2)
t1 = 2011 (j = 1) [11.30%, 13.67%] [86.33%, 88.73%]
t2 = 2012 (j = 2) [14.8%, 21.60%] [78.20%, 85.20%]
Table 3
95% CI of the data surveys using the probability mass function of Beta-Binomial
distributions given by (15)–(18).
We apply the same method explained above but considering Y j1 = # Carriers
of Meningococcus W , Y j2 = # Carriers of non-Meningococcus W and n1 =
3000 and n2 = 500. Therefore, we assume that




2), j = 1, 2,
and consequently,




1) j = 1, 2.
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Thus, their probability mass functions are given by











, k = 0, 1, . . . , nj, j = 1, 2, (21)











, k = 0, 1, . . . , nj, j = 1, 2. (22)
The parameters γji , 1 ≤ i, j ≤ 2, are estimated using the MLE technique and
we have obtained
γ11 = 121.9, γ
1
2 = 2727.7; γ
2
1 = 11.1872, γ
2
2 = 192.4464.
In Table 4, we show the 95% CI for each the random variables {Y 11 , Y 21 , Y 12 , Y 22 }
computing the percentiles 2.5 and 97.5 of each random vector Y1 = (Y 11 , Y
1
2 )
and Y2 = (Y 21 , Y
2
2 ).
Dates Genotype W (Y j1 ) Genotype non-W (Y
j
2 )
t1 = 2011 (j = 1) [3.52%, 4.97%] [95.03%, 96.43%]
t2 = 2012 (j = 2) [3.8%, 7.7%] [92.30%, 96.2%]
Table 4
95% CI of the data surveys using the probability mass function of Beta-Binomial
distributions given by (21)–(22).
3.2 Probabilistic estimation
Let M1(t; β, γ) and M2(t;α,N1) denote short representations of model (2) and
(14), respectively, where {β, γ}, and {α,N1} are the models parameters of M1
and M2, respectively, and t is the time in months.
Also, we have the data (95% CI) collected in Tables 3 and 4 obtained by
sampling the probability mass functions given by (15)–(18) and (21)–(22),
respectively, and calculating the percentiles 2.5 and 97.5.
For the probability distributions given in Eq. (15)–(18), we take a sample d∗tij,













is as minimum as possible, being ‖ · ‖2 the 2−norm [20].
This procedure is a classic optimization problem that has been carried out
through the Particle Swarm Optimization (PSO) algorithm [21], with the dif-
ference that we will not fit the data itself, but samples taken from the data’s
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probability distributions. We shall perform the fitting N times (N being a
large number), storing both the parameter values β∗, γ∗ as well as the cal-
culated errors e∗, ordered from smallest to largest values. The result of this
procedure is a list of model parameters fitted to a sample of the data with
their corresponding errors, represented in Table 5.
Error Parameters Model
e∗1 β
1, γ1 M1(t;β1, γ1)
e∗2 β





N , γN M1(t;βN , γN )
Table 5
Model fitting to N samples of the data’s probability distributions.
The value N should be a large number in order to capture as more data
uncertainty as possible during the sampling process and this uncertainty could
be fitted by the model. In this case, N = 10 000.
Now, we take M1(t; β1, γ1) and M1(t; β2, γ2) in Table 5 and calculate the
outputs for times t1 = 0 (Dec 2011) and t2 = 11 (Dec 2012), the time instants
(months) where data are available. For each time instant, we shall calculate
percentiles 2.5 and 97.5 for carriers. Hence, we will name m2 the sum of:
• the 2−norm of the difference between the percentiles 2.5 from the model
output and from the data percentiles 2.5 in Table 3, and
• the 2−norm of the difference between the percentiles 97.5 from the model
output and from the data percentiles 97.5 in Table 3.
We will repeat the above process with the outputs from M1(t; β1, γ1), M1(t; β2, γ2)
and M1(t; β3, γ3), obtaining m3, the measure between the confidence intervals
from the outputs and the data. The same for m4 and so on, until M1(t; β1, γ1),
M1(t; β2, γ2), . . ., M1(t; βN , γN), obtaining mN as the measure between the
confidence intervals from the outputs and the data.
Taking mk = min{m1, . . . ,mN}, we ensure that the 95% CI bands of the
outputs from M1(t; β1, γ1), M1(t; β2, γ2), . . . ,M1(t; βk, γk) is the closest to the
95% confidence intervals from the data, with which our model will capture
the maximum possible uncertainty of the data from the output of the models
M1(t; β1, γ1), M1(t; β2, γ2), . . . , M1(t; βk, γk).
This procedure should be repeated for model M2(t;α,N1) by sampling the
probability mass functions given by Eq. (21)–(22).
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4 Results
For the SCS model M1(t; β, γ), we obtain mk = 5211. With the outputs of
M1(t; β1, γ1), . . ., M1(t; β5211, γ5211) for t = 0, 1, . . . , 119 (from Dec 2011 until
Dec 2020), we can predict, probabilistically, the transmission dynamics of
the carriers. Then, for each time instant t we take the model output and we
calculate the 95% CI and the mean of the expectation. The results are shown
in Figure 2.












Fig. 2. 95% CI of the solution stochastic process of the percentage of carriers given
by model (2). The dotted line represents the percentile 97.5, the dashed line, the
percentile 2.5 and the solid line, the mean, for each month, t, from Dec 2011 until
Dec 2021.
The probabilistic fitting technique allows us to estimate the density functions
for model parameters applying the so-called kernel technique to the 5211 sam-
ples of parameters β, γ obtained [22, ch. 8]. These density functions can be
seen in Figure 3.
Now, let us observe Figure 3. This plot gives us an idea about the time an
individual needs to clear meningococcus bacteria looking at parameter γ. The
95% confidence interval of γ is [0.1007, 0.7895], and taking into account that
1/γ is the average time to clear the meningococcus, we have that the estimated
time needed to clear any meningococcus bacterium is [1/0.7895, 1/0.1007] =
[1.26662, 9.93049] months with 95% CI. These figures are in accordance with
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Fig. 3. Probability density functions for the parameters β (dashed line) and γ (solid
line) of model (2). Notice that there are non-zero probabilities for negative values
of these parameters, although in any reasonable epidemiological model they are
considered positive. This feature is a consequence of the kernel technique and these
negative unrealistic values can be overlooked.
the ones in the extant literature [10].
We can perform similar calculations for the Lotka-Volterra model M2(t;α,N1).
In this case, we have obtained mk = 651 with N = 10 000.
Notice that the order of the fractional derivative, α is far from 1 (that cor-
responds to the classical derivative) as we can see in Figure 5. Specifically,
the mean of the pdf of α shown in this plot is 0.371326. Its 95% CI is
[0.004352, 0.7383]. This supports the idea of the necessity of using fractional
derivatives against classical derivatives in order to explain properly the com-
petitiveness dynamics among the different genogroups of meningococci.
Finally, the product of both solution stochastic processes, Ct and xt, of models
(2) and (14), respectively, will give us the percentage of Men W-135 carriers
among all the population. In a personal communication, Dr. Julio Vázquez,
from the Neisserias Reference Laboratory for Meningococcus of the Spanish
Institute of Health Carlos III, told us that a percentage of 4%−5% or greater
of carriers of Men W-135 in Spain would begin to be concerning.
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Fig. 4. Confidence intervals of the solution stochastic process for the percentage of
meningococcus W-135 computed by the numerical scheme given in Eq. (14). The
dotted line represents the percentile 97.5, the dashed line, the percentile 2.5 and the
solid line, the mean, for each time, t, from Dec 2011 until Dec 2020.
Finally, taking into account the probabilistic information obtained previously
for all time instants t, we are able to calculate the probability that the percent-
age of carriers of Men W-135 be greater than 5%. In Table 6 we can see the
obtained results. In Figure 6 a graph with the evolution of the probabilities of
having 5% of carriers of Men W-135 or more from Dec 2011 until Dec 2021.
with the combined
Date Probability W-135 ≥ 5%





Probability that the percentage of carriers of Men W-135 be greater than 5%.
As we can see, the probability of having worrying percentages of carriers of
Men W-135 is very low and, then, an outbreak is not expected.
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Fig. 5. Probability density functions (pdf’s) for the parameters of the Lotka-Volterra
model. The dashed line corresponds to the parameter N1 and the solid line to the
fractional derivative order, α. The short piece of negative values of the α parameter
that appears in the plot, is a feature of the application of the so-called kernel tech-
nique used to construct the pdf’s. This piece must been neglected since 0 < α < 1.
5 Conclusions
In this paper we have proposed a probabilistic model for the complex ecosys-
tem composed by several meningococcal genogroups and the human hosts
carriers. The competition among the different genogroups has been discussed
in the framework of a Lotka-Volterra model with fractional derivatives. The
Lotka-Volterra system is a well-known tool for simulating different population
of the same species competing for the same resources and it has been applied
in ecology and evolutionary models. Our model is generalized taking advan-
tage of fractional calculus in order to consider the effects of the memory of
this competition in the form of genetic changes of the strains.
The interaction with the human hosts is described in terms of a discrete
susceptible-infectious-susceptible model in which the infectious are called car-
riers. This SCS model involves two parameters corresponding to the average
time of recovery from the carrier state, 1/γ, and the infective rate, β. We
must also notice that meningococcal disease is very difficult to analyze through
seroepidemiological studies because of the low carriage at a given time and the
17



























Fig. 6. Probability of having 5% of carriers of Men W-135 or more in Spain. Pre-
diction from Dec 2011 until Dec 2021.
continuous mutation and recombination of DNA in the strains. For that rea-
son, only a few mathematical models have been considered and, in particular,
very little is known about the epidemiology of the W-135 genogroup which
has caused recent outbreaks in Chile and the United Kingdom. Immigration
from Africa is thought to be the main cause of the emergence of these strains
in America and Europe where they were almost nonexistent or very rare even
a decade ago. This is a reason of major concern for Public Health policies
because of the high mortality rate for cases of invasive W-135 meningococcal
disease.
In Spain there have been two seroepidemiological studies in 2011 and 2012 in
which the W-135 genogroup was found in a small percentage of individuals.
By fitting the results using a probabilistic approach, we have been able to
determine the probability densities for the parameters of the Lotka-Volterra
and SCS model. On the other hand, the prediction for the increase of W-135
in the near future shows that the probability for the carrier population to
surpass the critical threshold of 5% is below a 0.3% and so we can fairly say
that an outbreak of W-135 in Spain, under the present population and immi-
gration conditions, is negligible. On the other hand, our model does not take
into account an increase of W-135 carrier proportion in Africa, UK or South
America and the corresponding risk of further contact of Spanish population
with some of these carriers who could arrive to Spain.
18
Finally, we want to point out that, the effects of outbreaks in other countries
in the present globalized world which takes into account immigration rates and
the possibility of increased arrival of W-135 carriers as well as their contact
with the native population is a problem that should be addressed in a future
extended model to be discussed elsewhere.
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Appendix A
For the sake of completeness, in this appendix we show two properties related
with the binomial and beta distributions that have been required throughout
the manuscript.
A key property of the binomial distribution. Let X be a binomial ran-
dom variable of parameters n and p, X ∼ Bi(n; p). Then, it results as the sum
of n independent and identically distributed (iid) Bernoulli random variables





 0 with probability 1− p,1 with probability p, 1 ≤ i ≤ n.
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Xi = n−X ∼ Bi(n; 1− p).
A key property of the beta distribution. Let X be a beta distribution of
parameters β1 > 0 and β2 > 0, X ∼ Be(β1; β2). Then, its probability density




xβ1−1(1− x)β2−1, 0 < x < 1.
Let us consider the random variable Y = 1−X. Applying the random variable
transformation technique [27, ch.5], we can derive the pdf of Y , fY (y). Observe
that the mapping r : [0, 1] → [0, 1] defined by y = r(x) = 1 − x is bijective,
its inverse is s(y) = 1− y and its Jacobian is non-zero, ds(y)
dy
= −1 6= 0. Then,
according to the so-called Fundamental Theorem [27, p. 93] one gets,
fY (y) = fX(s(y))
∣∣∣∣∣ds(y)dy
∣∣∣∣∣ = Γ(β1 + β2)Γ(β1)Γ(β2)(1− y)β1−1yβ2−1, 0 < y < 1.
As a consequence, we have proved that if X ∼ Be(β1; β2), then 1 − X ∼
(β2; β1).
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